These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27245070)

  • 1. Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
    Barnes GD; Stanislawski MA; Liu W; Barón AE; Armstrong EJ; Ho PM; Klein A; Maddox TM; Nallamothu BK; Rumsfeld JS; Tsai TT; Bradley SM
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):406-13. PubMed ID: 27245070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Sukul D; Seth M; Schreiber T; Hanzel G; Khandelwal A; Cannon LA; Lalonde TA; Gurm HS
    J Interv Cardiol; 2017 Aug; 30(4):291-300. PubMed ID: 28543770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program.
    Aggarwal V; Armstrong EJ; Liu W; Maddox TM; Ho PM; Carey E; Wang T; Sherwood M; Tsai TT; Rumsfeld JS; Bradley SM
    Clin Cardiol; 2016 Oct; 39(10):578-584. PubMed ID: 27788301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
    Xie JX; Gunzburger EC; Kaun L; Plomondon ME; Barón AE; Waldo SW; Virani SS; Maddox TM; Mavromatis K
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005455. PubMed ID: 31665896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal Trends, Complications, and Predictors of Outcomes Among Nonagenarians Undergoing Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
    Sawant AC; Josey K; Plomondon ME; Maddox TM; Bhardwaj A; Singh V; Rajagopalan B; Said Z; Bhatt DL; Corbelli J
    JACC Cardiovasc Interv; 2017 Jul; 10(13):1295-1303. PubMed ID: 28683935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Lazar J; Cavusoglu E
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.
    Gurm HS; Smith DE; Collins JS; Share D; Riba A; Carter AJ; LaLonde T; Kline-Rogers E; O'Donnell M; Changezi H; Zughaib M; Safian R; Moscucci M;
    J Am Coll Cardiol; 2008 Feb; 51(5):529-35. PubMed ID: 18237680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous Coronary Intervention in Native Coronary Arteries Versus Bypass Grafts in Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
    Brilakis ES; O'Donnell CI; Penny W; Armstrong EJ; Tsai T; Maddox TM; Plomondon ME; Banerjee S; Rao SV; Garcia S; Nallamothu B; Shunk KA; Mavromatis K; Grunwald GK; Bhatt DL
    JACC Cardiovasc Interv; 2016 May; 9(9):884-93. PubMed ID: 27085582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
    Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions.
    Long KH; Ting HH; McMurtry EK; Lennon RJ; Wood DL; Holmes DR; Raveendran G; Rihal CS
    Value Health; 2008; 11(3):462-9. PubMed ID: 18489669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
    Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
    J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry.
    Baber U; Dangas G; Chandrasekhar J; Sartori S; Steg PG; Cohen DJ; Giustino G; Ariti C; Witzenbichler B; Henry TD; Kini AS; Krucoff MW; Gibson CM; Chieffo A; Moliterno DJ; Weisz G; Colombo A; Pocock S; Mehran R
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1349-57. PubMed ID: 27388822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.
    Midei MG; Coombs VJ; Lowry DR; Drossner MN; Prewitt KC; Wang JC; Loughrey MB; Gottlieb SO
    Cardiology; 2007; 107(3):172-7. PubMed ID: 16940721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoption of transradial percutaneous coronary intervention and outcomes according to center radial volume in the Veterans Affairs Healthcare system: insights from the Veterans Affairs clinical assessment, reporting, and tracking (CART) program.
    Gutierrez A; Tsai TT; Stanislawski MA; Vidovich M; Bryson CL; Bhatt DL; Grunwald GK; Rumsfeld J; Rao SV
    Circ Cardiovasc Interv; 2013 Aug; 6(4):336-46. PubMed ID: 23941860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction.
    Raveendran G; Ting HH; Best PJ; Holmes DR; Lennon RJ; Singh M; Bell MR; Long KH; Rihal CS
    Mayo Clin Proc; 2007 Feb; 82(2):196-202. PubMed ID: 17290727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.